1
2
artículo
Publicado 2024
Enlace
Enlace
Background: Capivasertib is a potent, selective pan-AKT inhibitor. In CAPItello-291, the addition of capivasertib to fulvestrant resulted in a statistically significant (P < 0.001) improvement in progression-free survival over fulvestrant monotherapy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer and disease progression on or after aromatase inhibitor-based therapy. Characterization of the capivasertib-fulvestrant adverse event (AE) profile as managed in CAPItello-291 can inform future management guidance and optimize clinical benefit. Patients and methods: Seven hundred and eight patients were randomized 1 : 1 to capivasertib (400 mg twice daily; 4 days on, 3 days off) or placebo, plus fulvestrant, on a 4-week cycle. Dose reductions/interruptions for capivasertib/placebo were permitted (up to two dose reductions). S...
3
artículo
Publicado 2018
Enlace
Enlace
This research was supported by FONDECYT, Chile Grant 1140785, Postdoctoral Grant 3050046 and CONICYT Chile (Beca de Apoyo a Tesis Doctoral), Morris Animal Foundation (D05LA-002), Darwin Initiative for the Survival of Species (United Kingdom) 1312 grant 162/06/126, The British Embassy (Lima), NERC 1313 (United Kingdom) grant GST/02/828, and Newton Fund Researcher Links Travel grant (ID: RLTG9-LATAM-359537872) funded by the UK Department for Business, Energy and Industrial Strategy and CONCYTEC (Peru) and delivered by the British Council.
4
artículo
Phylogeography and Population Genetics of Vicugna vicugna: Evolution in the Arid Andean High Plateau
Publicado 2019
Enlace
Enlace
In Peru, research was supported by Darwin Initiative for the Survival of Species (United Kingdom) grant 162/06/126 (1997-2000), The British Embassy (Lima), NERC (United Kingdom) grant GST/02/828 (1994-1998), the European Commission INCO-DC ICA4-2000-10229, MACS (2001-2005), and a Newton Fund Researcher Links Travel grant (ID: RLTG9-LATAM-359537872) funded by the United Kingdom Department for Business, Energy and Industrial Strategy and CONCYTEC (Peru) and delivered by the British Council; Asociacion Ancash, Peru (2004); FINCyT Peru grant 006-FINCyT-PIBAP-2007 (2008-2010); and COLP, Compania Operadora de LNG del Peru contract PLNG-EV-09012 (2010-2011).
5
artículo
Publicado 2024
Enlace
Enlace
What is this summary about?: This is a summary of the article discussing the results of the CAPItello-291 study. In the study, participants had advanced breast cancer that could not be completely removed with surgery, and that was diagnosed as a type of breast cancer where tumor cells had hormone receptors (HR-positive) but did not have HER2 receptors (HER2-negative). All participants were also required to have previously received treatment with a type of therapy called an aromatase inhibitor (with or without a CDK4/6 inhibitor), but over time their cancer cells had still grown or spread. The CAPItello-291 study researchers wanted to find out if a treatment combination of the medications capivasertib plus fulvestrant worked better than placebo plus fulvestrant. Capivasertib is a drug that blocks the activity of a protein called AKT, which is found inside breast cancer cells. What are the...
6
artículo
Background AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor-positive advanced breast cancer are limited. Methods In a phase 3, randomized, double-blind trial, we enrolled eligible pre-, peri-, and postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer who had had a relapse or disease progression during or after treatment with an aromatase inhibitor, with or without previous cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy. Patients were randomly assigned in a 1:1 ratio to receive capivasertib plus fulvestrant or placebo plus fulvestrant. The dual primary end point was investigator-assessed progression-free survival assessed both in the overal...
7
artículo
Publicado 2013
Enlace
Enlace
ABSTRACT Introduction Optimal management of sedation, analgesia and delirium offers comfort and security for the critical care patient, allows support measures to be applied more easily and enables an integral approach of medical care, but at the same time lowers the incidence of complications, which translates in better patient outcomes. Objective To update the Guía de práctica clínica basada en la evidencia para el manejo de la sedoanalgesia en el paciente adulto críticamente enfermo published in Medicina Intensiva in 2007, and give recommendations for the management of sedation, analgesia, and delirium. Methodology A group of 21 intensivists from 9 countries of the Federación Panamericana e Ibérica de Sociedades de Medicina Crítica y Terapia Intensiva, 3 of them also specialists in clinical epidemiology and methodology, gathered for the development of guidelines. Assessment of ...
8
artículo
Publicado 2018
Enlace
Enlace
Purpose: Prognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) and overall survival (OS) according to degree of pathologic response in patients treated with carboplatin plus docetaxel NAC. Patients and methods: One-hundred and ninety patients with stage I-III TNBC were treated with neoadjuvant carboplatin (AUC6) plus docetaxel (75 mg/m2) every 21 days × 6 cycles. pCR (no evidence of invasive tumor in breast and axilla) and Residual cancer burden (RCB) were evaluated. Patients were followed for recurrence and survival. Extent of pathologic response was associated with RFS and OS using the Kaplan-Meier method. Results: Median age was 51 years, and 52% were node-positive. pCR and ...
9
artículo
Publicado 2020
Enlace
Enlace
This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients. It provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care. Updated diagnostic and treatment algorithms are also provided. All recommendations were compiled by a multidisciplinary group of international experts. Recommendations are based on available clinical evidence and the collective expert opinion of the authors.
